· The Phase 2 trial is an important step in the dual product development of ZP4207: both as a rescue pen to treat severe hypoglycemia and as an essential component in an artificial pancreas device for better diabetes control

· Advancing ZP4207 into Phase 2 development is in line with Zealand's strategic focus on growing its pipeline of proprietary peptide medicines for accelerated value creation

· Trial completion and results are expected in H2 2016

COPENHAGEN, Denmark, Feb. 4, 2016 (GLOBE NEWSWIRE) -- Zealand informs that the first patients have successfully been dosed in a Phase 2 trial with ZP4207 for the treatment and control of hypoglycemia associated with diabetes. ZP4207 is a novel stable glucagon analogue for liquid formulation, invented and fully owned by Zealand.

Attachments:

PR 01-16_0204 - Glucagon analogue ZP4207 advanced into Phase 2 - ENG_Final.pdf

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.